|
Synonyms: Adcetris® | anti-CD30 ADC SGN-35 | SGN 35
brentuximab vedotin is an approved drug (FDA (2011), EMA (2012))
Compound class:
Antibody
Comment: Antibody-drug conjugate (ADC) that combines an anti-CD30 antibody and the drug monomethyl auristatin E (MMAE). The PubChem ID for the MMAE component compound is CID 11542188. The invention of this ADC is claimed in patent US7090843 [4] and the original article describing the parent antibody (C10 or AC10) is [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
| Immunopharmacology Comments |
| Brentuximab vedotin is an ADC targeting CD-30 positive tumour cells. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Systemic scleroderma |
Disease Ontology:
DOID:418 OMIM: 181750 Orphanet: ORPHA90291 |
Phase 1/2 clinical candidate for systemic sclerosis- see NCT03222492 and NCT03198689 | |
| Mastocytosis |
Disease Ontology:
DOID:350 |
Phase 2 clinical candidate for aggressive systemic mastocytosis, mast cell leukemia and systemic mastocytosis- see NCT01807598 | |
| Systemic lupus erythematosus |
Disease Ontology:
DOID:9074 OMIM: 152700 Orphanet: ORPHA536 |
Ex Phase 2 clinical candidate for adults with SLE- trial NCT02533570 was terminated | |
| Mycosis fungoides |
OMIM:
254400 Orphanet: ORPHA2584 |
Approved drug for CD-30 positive MF. | 3 |
| Anaplastic large cell lymphoma |
Disease Ontology:
DOID:0050744 |
Approved drug for systemic anaplastic large cell lymphoma, and primary cutaneous ALCL. | |
| Lymphoma, Hodgkin, Classic; CHL |
Disease Ontology:
DOID:8567 OMIM: 236000 |
Approved drug for HL. | |
